AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

Submitted by admin on Wed, 05/27/2015 - 00:59

AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Submitted by admin on Fri, 05/01/2015 - 01:27

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Occam Global is a strategic executive search firm with substantial experience serving entrepreneurial companies in the Healthcare and Technology sectors.

USCACA Board of Director Member in the News

Submitted by admin on Fri, 03/20/2015 - 09:20

Jan. 21st, 2015, Paris

2014 Chinese Clinical Oncology Advances Awards Announced

Submitted by admin on Thu, 02/05/2015 - 01:38

2014 Chinese Clinical Oncology Advances Awards Announced
From China Medical Tribune

USCACA sponsor - Chipscreen has its drug approved in China

Submitted by admin on Wed, 02/04/2015 - 01:19

Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).

Pages